Mind Medicine (MindMed) Inc
MNMD13.430USD
-0.590-4.21%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM
More Details of Mind Medicine (MindMed) Inc Company
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Mind Medicine (MindMed) Inc Info
Ticker SymbolMNMD
Company nameMind Medicine (MindMed) Inc
IPO dateMay 04, 2015
CEOBarrow (Robert B)
Number of employees74
Security typeOrdinary Share
Fiscal year-endMay 04
AddressOne World Trade Center
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10007
Phone12122206633
Websitehttps://ir.mindmed.co/
Ticker SymbolMNMD
IPO dateMay 04, 2015
CEOBarrow (Robert B)
Company Executives of Mind Medicine (MindMed) Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 12
Updated: Fri, Dec 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.34%
Commodore Capital LP
3.27%
Driehaus Capital Management, LLC
3.16%
Blackstone Alternative Asset Management, L.P.
2.82%
Marshall Wace LLP
2.42%
Other
83.00%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.34%
Commodore Capital LP
3.27%
Driehaus Capital Management, LLC
3.16%
Blackstone Alternative Asset Management, L.P.
2.82%
Marshall Wace LLP
2.42%
Other
83.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
16.21%
Investment Advisor
11.67%
Hedge Fund
11.27%
Research Firm
1.58%
Individual Investor
0.85%
Private Equity
0.37%
Bank and Trust
0.22%
Pension Fund
0.13%
Venture Capital
0.10%
Other
57.60%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
385
42.65M
43.29%
-5.82M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.22M
6.86%
+17.02K
+0.33%
Jun 30, 2025
Commodore Capital LP
5.00M
6.57%
+475.00K
+10.50%
Jun 30, 2025
Driehaus Capital Management, LLC
3.09M
4.06%
-258.75K
-7.72%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.71%
--
--
Jun 30, 2025
Marshall Wace LLP
3.42M
4.5%
+828.07K
+31.93%
Jun 30, 2025
Octagon Capital Advisors LP
2.13M
2.8%
-888.00K
-29.42%
Jun 30, 2025
The Vanguard Group, Inc.
1.80M
2.37%
+47.45K
+2.70%
Jun 30, 2025
State Street Investment Management (US)
1.81M
2.37%
-36.32K
-1.97%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.73M
2.28%
+66.66K
+4.00%
Jun 30, 2025
Deep Track Capital LP
2.50M
3.29%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
AdvisorShares Psychedelics ETF
9.95%
State Street SPDR S&P Pharmaceuticals ETF
2.17%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.54%
Virtus LifeSci Biotech Clinical Trials ETF
1.32%
iShares U.S. Pharmaceuticals ETF
0.4%
iShares Micro-Cap ETF
0.21%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
Nuveen ESG Small-Cap ETF
0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
0.07%
View more
AdvisorShares Psychedelics ETF
Proportion9.95%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.17%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.54%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.32%
iShares U.S. Pharmaceuticals ETF
Proportion0.4%
iShares Micro-Cap ETF
Proportion0.21%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
Nuveen ESG Small-Cap ETF
Proportion0.08%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Date
Type
Ratio
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
FAQs
Who are the top five shareholders of Mind Medicine (MindMed) Inc?
The top five shareholders of Mind Medicine (MindMed) Inc are:
BlackRock Institutional Trust Company, N.A. holds 5.22M shares, accounting for 6.86% of the total shares.
Commodore Capital LP holds 5.00M shares, accounting for 6.57% of the total shares.
Driehaus Capital Management, LLC holds 3.09M shares, accounting for 4.06% of the total shares.
Blackstone Alternative Asset Management, L.P. holds 3.59M shares, accounting for 4.71% of the total shares.
Marshall Wace LLP holds 3.42M shares, accounting for 4.50% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.22M shares, accounting for 6.86% of the total shares.
Commodore Capital LP holds 5.00M shares, accounting for 6.57% of the total shares.
Driehaus Capital Management, LLC holds 3.09M shares, accounting for 4.06% of the total shares.
Blackstone Alternative Asset Management, L.P. holds 3.59M shares, accounting for 4.71% of the total shares.
Marshall Wace LLP holds 3.42M shares, accounting for 4.50% of the total shares.
What are the top three shareholder types of Mind Medicine (MindMed) Inc?
The top three shareholder types of Mind Medicine (MindMed) Inc are:
BlackRock Institutional Trust Company, N.A.
Commodore Capital LP
Driehaus Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
Commodore Capital LP
Driehaus Capital Management, LLC
How many institutions hold shares of Mind Medicine (MindMed) Inc (MNMD)?
As of 2025Q3, 385 institutions hold shares of Mind Medicine (MindMed) Inc, with a combined market value of approximately 42.65M, accounting for 43.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.68%.
What is the biggest source of revenue for Mind Medicine (MindMed) Inc?
In --, the -- business generated the highest revenue for Mind Medicine (MindMed) Inc, amounting to -- and accounting for --% of total revenue.
